Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:MCRBNASDAQ:TELONYSE:VHAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.65-0.4%$0.55$0.40▼$1.17$13.45M2.14501,348 shs92,236 shsMCRBSeres Therapeutics$7.26+1.8%$9.11$6.53▼$30.60$63.39M2.89145,569 shs63,370 shsTELOTelomir Pharmaceuticals$2.01-4.7%$2.51$1.86▼$8.40$59.82M-0.38146,257 shs1.56 million shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shs99 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.87%-13.32%+18.18%+36.84%-20.73%MCRBSeres Therapeutics+1.86%+1.13%-22.75%-51.50%-66.68%TELOTelomir Pharmaceuticals+3.43%+1.93%-17.90%-49.03%-61.21%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%+10.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.4852 of 5 stars0.02.00.00.02.30.80.6MCRBSeres Therapeutics2.9584 of 5 stars2.91.00.04.62.00.80.0TELOTelomir Pharmaceuticals2.5172 of 5 stars3.81.00.00.03.10.00.6VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AMCRBSeres Therapeutics 1.80Reduce$73.67914.69% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00646.27% UpsideVHAQViveon Health Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AIMD, VHAQ, TELO, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.003/20/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/14/2025MCRBSeres TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $15.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$106.21K126.63N/AN/A$5.23 per share0.12MCRBSeres Therapeutics$126.33M0.50N/AN/A($0.35) per share-20.74TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$13.77M-$1.29N/A∞N/AN/A-75.16%-50.22%8/4/2025 (Estimated)MCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%8/12/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%8/12/2025 (Estimated)VHAQViveon Health Acquisition-$610KN/A0.00∞N/AN/AN/AN/AN/ALatest AIMD, VHAQ, TELO, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/A3/7/2025Q4 2024AIMDAinosN/A-$0.26N/A-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.501.371.33MCRBSeres TherapeuticsN/A1.121.12TELOTelomir PharmaceuticalsN/A1.941.94VHAQViveon Health AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AMCRBSeres Therapeutics59.34%TELOTelomir PharmaceuticalsN/AVHAQViveon Health Acquisition22.14%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%MCRBSeres Therapeutics4.70%TELOTelomir PharmaceuticalsN/AVHAQViveon Health Acquisition75.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million12.62 millionNot OptionableMCRBSeres Therapeutics3308.73 million162.03 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/AVHAQViveon Health Acquisition25.66 million1.40 millionNot OptionableAIMD, VHAQ, TELO, and MCRB HeadlinesRecent News About These CompaniesViveon Health Acquisition CorpNovember 21, 2024 | investing.comClearday, Inc. (CLRD)September 6, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - UpdatedMay 3, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future SuccessMay 2, 2024 | finance.yahoo.comViveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination ProcessFebruary 28, 2024 | finanznachrichten.deVIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESSFebruary 27, 2024 | globenewswire.comNYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)February 21, 2024 | finance.yahoo.comViveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSEDecember 27, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)December 22, 2023 | tmcnet.comSan Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.November 13, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)October 24, 2023 | finance.yahoo.comVHAQ-R Viveon Health Acquisition Corp.September 23, 2023 | seekingalpha.comViveon Health Acquisition Received Audit Opinion With Going Concern ExplanationSeptember 15, 2023 | marketwatch.comVIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATIONSeptember 15, 2023 | finance.yahoo.comViveon Healthcare Increases Consideration Offered to Clearday ShareholdersSeptember 5, 2023 | finance.yahoo.comSPAC Viveon ups merger consideration for Clearday to $500MAugust 29, 2023 | msn.comViveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger AgreementAugust 29, 2023 | finance.yahoo.comVIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILINGApril 25, 2023 | finance.yahoo.comViveon Health Acquisition Corp. (VHAQ-RT)April 18, 2023 | finance.yahoo.com(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to MarketApril 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, VHAQ, TELO, and MCRB Company DescriptionsAinos NASDAQ:AIMD$0.65 0.00 (-0.35%) As of 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Seres Therapeutics NASDAQ:MCRB$7.26 +0.13 (+1.82%) Closing price 04:00 PM EasternExtended Trading$7.14 -0.12 (-1.58%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Telomir Pharmaceuticals NASDAQ:TELO$2.01 -0.10 (-4.74%) Closing price 04:00 PM EasternExtended Trading$1.96 -0.04 (-2.24%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Viveon Health Acquisition NYSE:VHAQ$11.00 0.00 (0.00%) As of 01/30/2025Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
